{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:04:31Z","timestamp":1786651471855,"version":"build-2736575974"},"reference-count":29,"publisher":"American Society of Hematology","issue":"12","license":[{"start":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:00:00Z","timestamp":1712880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,6,25]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>The phase 3 INO-VATE trial demonstrated higher rates of remission, measurable residual disease negativity, and improved overall survival for patients with relapsed\/refractory (R\/R) acute lymphoblastic leukemia (ALL) who received inotuzumab ozogamicin (InO) vs standard-of-care chemotherapy (SC). Here, we examined associations between genomic alterations and the efficacy of InO. Of 326 randomized patients, 91 (InO, n\u00a0= 43; SC, n\u00a0= 48) had samples evaluable for genomic analysis. The spectrum of gene fusions and other genomic alterations observed was comparable with prior studies of adult ALL. Responses to InO were observed in all leukemic subtypes, genomic alterations, and risk groups. Significantly higher rates of complete remission (CR)\/CR with incomplete count recovery were observed with InO vs SC in patients with BCR::ABL1\u2013like ALL (85.7% [6\/7] vs 0% [0\/5]; P\u00a0= .0076), with TP53 alterations (100% [5\/5] vs 12.5% [1\/8]; P\u00a0= .0047), and in the high-risk BCR::ABL1\u2013 (BCR::ABL1\u2013like, low-hypodiploid, KMT2A-rearranged) group (83.3% [10\/12] vs 10.5% [2\/19]; P\u00a0&amp;lt; .0001). This retrospective, exploratory analysis of the INO-VATE trial demonstrated potential for benefit with InO for patients with R\/R ALL across leukemic subtypes, including BCR::ABL1\u2013like ALL, and for those bearing diverse genomic alterations. Further confirmation of the efficacy of InO in patients with R\/R ALL exhibiting the BCR::ABL1\u2013like subtype or harboring TP53 alterations is warranted. This trial was registered at www.ClinicalTrials.gov as #NCT01564784.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023012430","type":"journal-article","created":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T14:55:50Z","timestamp":1712933750000},"page":"3226-3236","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":17,"title":["Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed\/refractory ALL"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8230-5312","authenticated-orcid":false,"given":"Yaqi","family":"Zhao","sequence":"first","affiliation":[{"name":"1Department of Pathology, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Douglas","family":"Laird","sequence":"additional","affiliation":[{"name":"2Translational Oncology, Late Development, Pfizer Inc, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7626-4043","authenticated-orcid":false,"given":"Kathryn G.","family":"Roberts","sequence":"additional","affiliation":[{"name":"1Department of Pathology, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolla","family":"Yafawi","sequence":"additional","affiliation":[{"name":"3Clinical Data Acquisition, Pfizer Inc, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"4Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7865-2306","authenticated-orcid":false,"given":"Daniel J.","family":"DeAngelo","sequence":"additional","affiliation":[{"name":"5Department of Medical Oncology\/Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Stelljes","sequence":"additional","affiliation":[{"name":"6Department of Medicine\/Hematology and Oncology, Universit\u00e4tsklinikum M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8945-5850","authenticated-orcid":false,"given":"Michaela","family":"Liedtke","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Stanford Cancer Institute, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Stock","sequence":"additional","affiliation":[{"name":"8Department of Medicine, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2291-8245","authenticated-orcid":false,"given":"Nicola","family":"G\u00f6kbuget","sequence":"additional","affiliation":[{"name":"9Department of Medicine II, Hematology\/Oncology, Goethe Universit\u00e4t, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2481-7504","authenticated-orcid":false,"given":"Susan","family":"O\u2019Brien","sequence":"additional","affiliation":[{"name":"10Division of Hematology\/Oncology, Medicine, University of California Irvine Medical Center, Orange, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[{"name":"4Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3424-2425","authenticated-orcid":false,"given":"Ryan D.","family":"Cassaday","sequence":"additional","affiliation":[{"name":"11Division of Hematology, University of Washington School of Medicine and Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie R.","family":"Loyd","sequence":"additional","affiliation":[{"name":"12Hartwell Center for Biotechnology, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Olsen","sequence":"additional","affiliation":[{"name":"12Hartwell Center for Biotechnology, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3776-0858","authenticated-orcid":false,"given":"Geoffrey","family":"Neale","sequence":"additional","affiliation":[{"name":"12Hartwell Center for Biotechnology, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueli","family":"Liu","sequence":"additional","affiliation":[{"name":"13Biostatistics, Pfizer Inc, Groton, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Vandendries","sequence":"additional","affiliation":[{"name":"14Global Product Development, Pfizer Inc, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0015-5902","authenticated-orcid":false,"given":"Anjali","family":"Advani","sequence":"additional","affiliation":[{"name":"15Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1871-1850","authenticated-orcid":false,"given":"Charles G.","family":"Mullighan","sequence":"additional","affiliation":[{"name":"1Department of Pathology, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,6,14]]},"reference":[{"issue":"11","key":"2024062415110886400_bib1","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"11","key":"2024062415110886400_bib2","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood.2020010144","article-title":"Molecular classification improves risk assessment in adult BCR\u2013ABL1\u2013negative B-ALL","volume":"138","author":"Paietta","year":"2021","journal-title":"Blood"},{"issue":"5","key":"2024062415110886400_bib3","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1182\/blood-2003-07-2466","article-title":"Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies","volume":"103","author":"DiJoseph","year":"2004","journal-title":"Blood"},{"issue":"15","key":"2024062415110886400_bib4","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1182\/bloodadvances.2016001925","article-title":"Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1\/2 study","volume":"1","author":"DeAngelo","year":"2017","journal-title":"Blood Adv"},{"issue":"4","key":"2024062415110886400_bib5","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S1470-2045(11)70386-2","article-title":"Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study","volume":"13","author":"Kantarjian","year":"2012","journal-title":"Lancet Oncol"},{"issue":"15","key":"2024062415110886400_bib6","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1002\/cncr.28136","article-title":"Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia","volume":"119","author":"Kantarjian","year":"2013","journal-title":"Cancer"},{"issue":"8","key":"2024062415110886400_bib7","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard care for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"2024062415110886400_bib8","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.32116","article-title":"Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study","volume":"125","author":"Kantarjian","year":"2019","journal-title":"Cancer"},{"issue":"4","key":"2024062415110886400_bib9","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/ajh.25394","article-title":"Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin","volume":"94","author":"Jabbour","year":"2019","journal-title":"Am J Hematol"},{"issue":"6","key":"2024062415110886400_bib10","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/cncr.33321","article-title":"Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed\/refractory acute lymphoblastic leukemia","volume":"127","author":"Stock","year":"2021","journal-title":"Cancer"},{"issue":"2","key":"2024062415110886400_bib11","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41588-018-0315-5","article-title":"PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia","volume":"51","author":"Gu","year":"2019","journal-title":"Nat Genet"},{"issue":"24","key":"2024062415110886400_bib12","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1182\/blood.2022015444","article-title":"Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia","volume":"139","author":"Kimura","year":"2022","journal-title":"Blood"},{"issue":"9","key":"2024062415110886400_bib13","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1101\/gr.107524.110","article-title":"The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data","volume":"20","author":"McKenna","year":"2010","journal-title":"Genome Res"},{"issue":"24","key":"2024062415110886400_bib14","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1182\/blood.2021014723","article-title":"Concurrent CDX2 cis-deregulation and UBTF::ATXN7L3 fusion define a novel high-risk subtype of B-cell ALL","volume":"139","author":"Passet","year":"2022","journal-title":"Blood"},{"issue":"24","key":"2024062415110886400_bib15","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"2024062415110886400_bib16","first-page":"3792","article-title":"Biologic and therapeutic implications of genomic alterations in acute lymphoblastic leukemia","volume":"10","author":"Iacobucci","year":"2021","journal-title":"J\u00a0Clin Med"},{"issue":"4","key":"2024062415110886400_bib17","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1080\/10428194.2017.1344839","article-title":"TP53 in adult acute lymphoblastic leukemia","volume":"59","author":"Salmoiraghi","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"2024062415110886400_bib18","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3389\/fonc.2019.00057","article-title":"Chk1 inhibition restores inotuzumab ozogamicin citotoxicity in CD22-positive cells expressing mutant p53","volume":"9","author":"Tirr\u00f2","year":"2019","journal-title":"Front Oncol"},{"issue":"2","key":"2024062415110886400_bib19","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1182\/blood-2014-02-558833","article-title":"TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy, and a poor prognosis","volume":"124","author":"Stengel","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2024062415110886400_bib20","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/ng.2532","article-title":"The genomic landscape of hypodiploid acute lymphoblastic leukemia","volume":"45","author":"Holmfeldt","year":"2013","journal-title":"Nat Genet"},{"issue":"3","key":"2024062415110886400_bib21","doi-asserted-by":"crossref","first-page":"a026286","DOI":"10.1101\/cshperspect.a026286","article-title":"TP53 mutations in hypodiploid acute lymphoblastic leukemia","volume":"7","author":"Comeaux","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"Supplement 1","key":"2024062415110886400_bib22","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1182\/blood-2020-142012","article-title":"Distinct prognostic effects of TP53 mutations in newly diagnosed versus relapsed\/refractory (R-R) patients (pts) with B-acute lymphoblastic leukemia (ALL) treated with mini-HCVD-inotuzumab ozogamicin with or without blinatumomab regimens","volume":"136","author":"Kanagal-Shamanna","year":"2020","journal-title":"Blood"},{"issue":"25","key":"2024062415110886400_bib23","doi-asserted-by":"crossref","first-page":"6521","DOI":"10.1182\/blood-2011-05-351403","article-title":"Dasatinib as first-line treatment for adult patients with Philadelphia chromosome\u2013positive acute lymphoblastic leukemia","volume":"118","author":"Fo\u00e0","year":"2011","journal-title":"Blood"},{"issue":"7","key":"2024062415110886400_bib24","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.3390\/cancers14071805","article-title":"Treatment of Philadelphia chromosome\u2013positive acute lymphoblastic leukemia in adults","volume":"14","author":"Saleh","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"10","key":"2024062415110886400_bib25","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1158\/1078-0432.CCR-20-2399","article-title":"Inotuzumab ozogamicin for relapsed\/refractory acute lymphoblastic leukemia in the INO-VATE trial: CD22 pharmacodynamics, efficacy, and safety by baseline CD22","volume":"27","author":"Kantarjian","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"16","key":"2024062415110886400_bib26","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1200\/JCO.2016.69.3531","article-title":"Complete hematologic and molecular response in adult patients with relapsed\/refractory Philadelphia chromosome\u2013positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study","volume":"35","author":"Martinelli","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"2024062415110886400_bib27","doi-asserted-by":"crossref","first-page":"E379","DOI":"10.1002\/ajh.26281","article-title":"Impact of Philadelphia chromosome-like alterations on efficacy and safety of blinatumomab in adults with relapsed\/refractory acute lymphoblastic leukemia: a post hoc analysis from the phase 3 TOWER study","volume":"96","author":"Jabbour","year":"2021","journal-title":"Am J Hematol"},{"issue":"4","key":"2024062415110886400_bib28","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1182\/blood.2020006287","article-title":"Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL","volume":"137","author":"Zhao","year":"2021","journal-title":"Blood"},{"issue":"4","key":"2024062415110886400_bib29","doi-asserted-by":"crossref","first-page":"565","DOI":"10.3324\/haematol.2017.185603","article-title":"The many faces of IKZF1 in B-cell precursor acute lymphoblastic leukemia","volume":"103","author":"Marke","year":"2018","journal-title":"Haematologica"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/12\/3226\/2232003\/blooda_adv-2023-012430-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/12\/3226\/2232003\/blooda_adv-2023-012430-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T15:11:29Z","timestamp":1719241889000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/12\/3226\/515390\/Association-of-leukemic-molecular-profile-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,14]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,6,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023012430","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,14]]}}}